JPS6041077B2
(ja)
|
1976-09-06 |
1985-09-13 |
喜徳 喜谷 |
1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
US5266573A
(en)
|
1989-08-07 |
1993-11-30 |
Elf Sanofi |
Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
ES2529190T3
(es)
|
1996-07-24 |
2015-02-17 |
Celgene Corporation |
2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
BR9908811A
(pt)
|
1998-03-16 |
2000-12-05 |
Celgene Corp |
Composto, composição farmacêutica e seu uso no tratamento de mamìferos
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
AU2003210787B2
(en)
|
2002-02-01 |
2009-04-23 |
Medinol Ltd. |
Phosphorus-containing compounds & uses thereof
|
PT1482924E
(pt)
|
2002-03-05 |
2008-08-27 |
Axys Pharm Inc |
Inibidores de proteases da cisteína catepsina
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
KR20150090263A
(ko)
|
2004-09-02 |
2015-08-05 |
제넨테크, 인크. |
헤지호그 신호전달에 대한 피리딜 억제제
|
CA2899923A1
(en)
|
2005-08-31 |
2007-03-08 |
Celgene Corporation |
Isoindole-imide compounds and compositions comprising and methods of using the same
|
US8445198B2
(en)
|
2005-12-01 |
2013-05-21 |
Medical Prognosis Institute |
Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
|
WO2007067500A2
(en)
|
2005-12-05 |
2007-06-14 |
Genomic Health, Inc. |
Predictors of patient response to treatment with egfr inhibitors
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
AU2007290407A1
(en)
|
2006-08-30 |
2008-03-06 |
Celgene Corporation |
5-substituted isoindoline compounds
|
CN101534820A
(zh)
|
2006-09-15 |
2009-09-16 |
细胞基因公司 |
N-甲基氨甲基异吲哚化合物和包含它的组合物及其使用方法
|
MY180812A
(en)
|
2007-03-20 |
2020-12-09 |
Celgene Corp |
4'-o-substituted isoindoline derivattives and compositions comprising and methods of using the same
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
MX2011004470A
(es)
*
|
2008-10-29 |
2011-05-31 |
Celgene Corp |
Compuestos de isoindolina para uso en el tratamiento de cancer.
|
US8551115B2
(en)
|
2009-09-23 |
2013-10-08 |
Intuitive Surgical Operations, Inc. |
Curved cannula instrument
|
MX337169B
(es)
|
2010-02-11 |
2016-02-16 |
Celgene Corp |
Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.
|
EP3266452B1
(en)
|
2011-03-11 |
2019-07-03 |
Mayo Foundation for Medical Education and Research |
Means to treat myelomas which are resistant to thalidomide, lenalidomide or pomalidomide
|
ES2699810T3
(es)
|
2012-06-29 |
2019-02-12 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon
|
WO2014028445A2
(en)
|
2012-08-14 |
2014-02-20 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
MX363437B
(es)
|
2012-12-13 |
2019-03-22 |
Novartis Ag |
Pirimido-4,5-b]-quinolina-4,5 (3h,10h)-dionas como supresoras de mutacion sin sentido.
|
JP6389241B2
(ja)
|
2013-04-17 |
2018-09-12 |
シグナル ファーマシューティカルズ,エルエルシー |
癌を治療するためのTORキナーゼ阻害剤及びIMiD化合物を含む組合せ療法
|
WO2014190207A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
WO2015006299A1
(en)
|
2013-07-08 |
2015-01-15 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical formulations of tranexamic acid and their use
|
CA2932120C
(en)
|
2013-12-06 |
2023-09-19 |
Celgene Corporation |
Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
|
US11366100B2
(en)
|
2014-02-12 |
2022-06-21 |
Dana-Farber Cancer Institute, Inc. |
P13K-MTORC1-S6K1 signaling pathway biomarkers predictive of anti-cancer responses
|
JP6576942B6
(ja)
|
2014-03-03 |
2019-11-27 |
マドリガル ファーマシューティカルズ インコーポレイテッド |
標的治療薬
|
MA39483A
(fr)
|
2014-03-18 |
2015-09-24 |
Synta Pharmaceuticals Corp |
Agents thérapeutiques cibles
|
KR20210132233A
(ko)
|
2014-04-14 |
2021-11-03 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
PL3182996T3
(pl)
|
2014-08-22 |
2023-04-17 |
Celgene Corporation |
Sposoby leczenia szpiczaka mnogiego związkami immunomodulującymi w kombinacji z przeciwciałami
|
US20180267043A1
(en)
|
2014-10-07 |
2018-09-20 |
Celgene Corporation |
Use of biomarkers for predicting clinical sensitivity to cancer treatment
|
WO2016065139A1
(en)
|
2014-10-24 |
2016-04-28 |
Fl Therapeutics Llc |
3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
|
DK3214081T3
(da)
|
2014-10-30 |
2020-09-28 |
Kangpu Biopharmaceuticals Inc |
Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
WO2016118666A1
(en)
|
2015-01-20 |
2016-07-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of the androgen receptor
|
WO2016197032A1
(en)
|
2015-06-04 |
2016-12-08 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
US20180147202A1
(en)
|
2015-06-05 |
2018-05-31 |
Arvinas, Inc. |
TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
EP3331906A1
(en)
|
2015-08-06 |
2018-06-13 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
GB201516243D0
(en)
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
CN105175285B
(zh)
|
2015-10-10 |
2017-05-03 |
山东大学 |
多靶点型他米巴罗汀衍生物及其制备方法和应用
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
KR20180095094A
(ko)
|
2016-01-08 |
2018-08-24 |
셀진 코포레이션 |
암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
|
SG10202007913WA
(en)
|
2016-01-08 |
2020-10-29 |
Celgene Corp |
Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
|
EP3416950A1
(en)
|
2016-02-16 |
2018-12-26 |
Massachusetts Institute of Technology |
Max binders as myc modulators and uses thereof
|
AU2017232906B2
(en)
|
2016-03-16 |
2022-03-31 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Small molecules against cereblon to enhance effector T cell function
|
US10759808B2
(en)
|
2016-04-06 |
2020-09-01 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
KR102447884B1
(ko)
|
2016-04-21 |
2022-09-27 |
바이오벤처스, 엘엘씨 |
항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도
|
WO2017197055A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
WO2017197051A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Amine-linked c3-glutarimide degronimers for target protein degradation
|
US11285218B2
(en)
|
2016-06-23 |
2022-03-29 |
Dana-Farber Cancer Institute, Inc. |
Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
|
WO2017223415A1
(en)
|
2016-06-23 |
2017-12-28 |
Dana-Farber Cancer Institute, Inc. |
Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use
|
AU2017326175B2
(en)
|
2016-09-13 |
2022-01-27 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as BET protein degraders
|
US11466028B2
(en)
|
2016-09-13 |
2022-10-11 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as BET protein degraders
|
KR102173463B1
(ko)
|
2016-10-11 |
2020-11-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적 분해용 화합물 및 방법
|
US11458123B2
(en)
|
2016-11-01 |
2022-10-04 |
Arvinas Operations, Inc. |
Tau-protein targeting PROTACs and associated methods of use
|
EP3535254A4
(en)
|
2016-11-01 |
2020-06-24 |
Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") |
COMPOUNDS FOR THE DEGRADATION OF MALT1
|
AU2017363265B2
(en)
|
2016-11-22 |
2021-11-04 |
Dana-Farber Cancer Institute, Inc. |
Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
|
EP3544957A4
(en)
|
2016-11-22 |
2020-09-02 |
Dana-Farber Cancer Institute, Inc. |
KINASE PROTEIN DEGRADATION BY CONJUGATION OF KINASE PROTEIN INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
|
US10842878B2
(en)
|
2016-11-22 |
2020-11-24 |
Dana-Farber Cancer Institute, Inc. |
Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
|
KR20190082989A
(ko)
|
2016-12-01 |
2019-07-10 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
EP3329923A1
(en)
|
2016-12-02 |
2018-06-06 |
University of Copenhagen |
The potential of crbn-independent imid resensitization by epigenetic therapy
|
WO2018106870A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
MX2019007649A
(es)
|
2016-12-23 |
2019-09-10 |
Arvinas Operations Inc |
Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
|
AU2017382406A1
(en)
|
2016-12-23 |
2019-04-18 |
Arvinas Operations, Inc. |
EGFR proteolysis targeting chimeric molecules and associated methods of use
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
CN117551089A
(zh)
|
2017-01-26 |
2024-02-13 |
阿尔维纳斯运营股份有限公司 |
***受体蛋白水解调节剂及相关使用方法
|
AU2018215212B2
(en)
|
2017-01-31 |
2022-06-02 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
EP4119552A1
(en)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
CA3053008A1
(en)
|
2017-02-08 |
2018-08-16 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
WO2018169777A1
(en)
|
2017-03-14 |
2018-09-20 |
Biotheryx, Inc. |
Compounds targeting proteins, compositions, methods, and uses thereof
|
CN108929307A
(zh)
|
2017-05-22 |
2018-12-04 |
苏州偶领生物医药有限公司 |
一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
|
EP3644999B1
(en)
|
2017-06-30 |
2022-12-14 |
Celgene Corporation |
Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
|
KR101904287B1
(ko)
|
2017-07-03 |
2018-10-04 |
효성전기주식회사 |
단순한 버스바 구조를 갖는 브러쉬리스 모터의 결선방법
|
IL271889B2
(en)
|
2017-07-10 |
2023-03-01 |
Celgene Corp |
Antisplit compounds and methods of their use
|
CN107698575A
(zh)
|
2017-09-26 |
2018-02-16 |
中国药科大学 |
cereblon配体介导的新型BET蛋白降解的双功能分子及其制备和应用
|
WO2019099868A2
(en)
|
2017-11-16 |
2019-05-23 |
C4 Therapeutics, Inc. |
Degraders and degrons for targeted protein degradation
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
MX2020006812A
(es)
|
2017-12-26 |
2020-11-06 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
EP3735243A4
(en)
|
2018-01-02 |
2021-08-25 |
Celgene Corporation |
ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
US11299485B2
(en)
|
2018-01-25 |
2022-04-12 |
Fujimoto Co., Ltd. |
Thiophene derivative and use thereof
|
US11220515B2
(en)
|
2018-01-26 |
2022-01-11 |
Yale University |
Imide-based modulators of proteolysis and associated methods of use
|
US11401336B2
(en)
|
2018-02-21 |
2022-08-02 |
Celgene Corporation |
BCMA-binding antibodies and uses thereof
|
US20210261538A1
(en)
|
2018-02-22 |
2021-08-26 |
Icahn School Of Medicine At Mount Sinai |
Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
|
WO2019170150A1
(zh)
|
2018-03-09 |
2019-09-12 |
上海科技大学 |
蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
|
WO2019177902A1
(en)
|
2018-03-10 |
2019-09-19 |
Yale University |
Modulators of btk proteolysis and methods of use
|
AU2019249849C1
(en)
|
2018-04-01 |
2022-09-29 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
CN112218859A
(zh)
|
2018-04-04 |
2021-01-12 |
阿尔维纳斯运营股份有限公司 |
蛋白水解调节剂及相关使用方法
|
KR102548191B1
(ko)
|
2018-04-09 |
2023-06-28 |
상하이테크 유니버시티 |
표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용
|
JP2021521192A
(ja)
|
2018-04-13 |
2021-08-26 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
セレブロンリガンドおよび同リガンドを含む二機能性化合物
|
ES2959622T3
(es)
|
2018-04-23 |
2024-02-27 |
Celgene Corp |
Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para tratar el linfoma
|
CA3101338A1
(en)
|
2018-06-13 |
2019-12-19 |
Biotheryx, Inc. |
Aminoamide compounds
|
CA3102214A1
(en)
|
2018-06-29 |
2020-01-02 |
Dana-Farber Cancer Institute, Inc. |
Ligands to cereblon (crbn)
|
CN110684015A
(zh)
|
2018-07-06 |
2020-01-14 |
四川大学 |
靶向alk的protac及其应用
|
CA3105506A1
(en)
|
2018-07-11 |
2020-01-16 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Dimeric immuno-modulatory compounds against cereblon-based mechanisms
|
US11045458B2
(en)
|
2018-07-23 |
2021-06-29 |
Wisconsin Alumni Research Foundation |
Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them
|
WO2020023480A1
(en)
|
2018-07-23 |
2020-01-30 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
CA3106239A1
(en)
|
2018-07-27 |
2020-01-30 |
Biotheryx, Inc. |
Bifunctional compounds as cdk modulators
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのe3ユビキチンリガーゼ結合活性を有するキメラ(protac)化合物を標的とし、アルファ-シヌクレインタンパク質を標的とするタンパク質分解
|
US20210363146A1
(en)
|
2018-08-22 |
2021-11-25 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (trk) degradation compounds and methods of use
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
KR102642203B1
(ko)
|
2018-09-07 |
2024-03-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법
|
US20220040317A1
(en)
|
2018-09-27 |
2022-02-10 |
Dana-Farber Cancer Institute, Inc. |
Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
|
CA3121667A1
(en)
|
2018-09-30 |
2020-04-02 |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences |
Isoindoline compound, preparation method, pharmaceutical composition and use thereof
|
SG11202102744PA
(en)
|
2018-10-16 |
2021-04-29 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Method for identifying a chemical compound or agent inducing ubiquitination of a protein of interest
|
AU2019377854A1
(en)
|
2018-11-08 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
EP3880669A1
(en)
|
2018-11-13 |
2021-09-22 |
Biotheryx, Inc. |
Substituted isoindolinones
|
CN111205282B
(zh)
|
2018-11-21 |
2023-12-01 |
上海科技大学 |
Er蛋白调节剂及其应用
|
WO2020118098A1
(en)
|
2018-12-05 |
2020-06-11 |
Vividion Therapeutics, Inc. |
Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
|
CN111285850B
(zh)
|
2018-12-06 |
2022-04-22 |
中国科学院上海药物研究所 |
一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
|
AU2020205643A1
(en)
|
2019-01-09 |
2021-08-19 |
Celgene Corporation |
Antiproliferative compounds and second active agents for use in treating multiple myeloma
|
GB2580675A
(en)
|
2019-01-23 |
2020-07-29 |
Wheelright Ltd |
Tyre sidewall imaging method
|
KR20200097222A
(ko)
|
2019-02-07 |
2020-08-18 |
한국화학연구원 |
표적 단백질 eed 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 eed, ezh2, 또는 prc2 관련 질환의 예방 또는 치료용 약학적 조성물
|
EP3924350A1
(en)
|
2019-02-13 |
2021-12-22 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
EP3930759A4
(en)
|
2019-02-27 |
2023-03-22 |
Cullgen (Shanghai), Inc. |
CYCLIC AMP RESPONSE ELEMENT (CBP) BINDING PROTEIN AND/OR E1A ADENOVIRAL BINDING PROTEIN OF 300 KDA DEGRADATION COMPOUNDS (P300) AND METHODS OF USE
|
WO2020200291A1
(en)
|
2019-04-02 |
2020-10-08 |
Cullgen (Shanghai) , Inc. |
Compounds and methods of treating cancers
|
EP3947368A4
(en)
|
2019-04-04 |
2023-01-04 |
Dana-Farber Cancer Institute, Inc. |
CDK2/5 DEGRADING AGENTS AND ASSOCIATED USES
|
CN114423463A
(zh)
|
2019-05-06 |
2022-04-29 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
EA202192910A1
(ru)
|
2019-05-24 |
2022-03-18 |
Байотерикс, Инк. |
Соединения, направленные на белки, и содержащие их фармацевтические композиции, и их терапевтическое применение
|
CA3136753A1
(en)
|
2019-05-31 |
2020-12-03 |
Frans BACULI |
Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
|
US20230149549A1
(en)
|
2019-06-10 |
2023-05-18 |
Kymera Therapeutics, Inc |
Smarca degraders and uses thereof
|
WO2020257278A2
(en)
|
2019-06-18 |
2020-12-24 |
Dana-Farber Cancer Institute, Inc. |
Small molecule target bromo/acetyl proteins and uses thereof
|
CN110305126A
(zh)
|
2019-06-19 |
2019-10-08 |
浙江省医学科学院 |
一种基于crbn配体诱导cdk4/6降解的化合物及其制备方法、药物组合物和应用
|
CN110372669B
(zh)
|
2019-06-19 |
2020-11-24 |
浙江省医学科学院 |
一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用
|
CN110204543B
(zh)
|
2019-06-27 |
2022-03-29 |
江苏省中医药研究院 |
一种基于Cereblon配体诱导BET降解的吡咯并吡啶酮类双功能分子化合物
|
US20230089916A1
(en)
|
2019-06-28 |
2023-03-23 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2021011631A1
(en)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Fused-glutarimide crbn ligands and uses thereof
|
US20230093080A1
(en)
|
2019-07-15 |
2023-03-23 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2021011871A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
US20230132715A1
(en)
|
2019-07-17 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
US11912699B2
(en)
|
2019-07-17 |
2024-02-27 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated
|
JP2021020879A
(ja)
|
2019-07-30 |
2021-02-18 |
学校法人東京医科大学 |
p63スプライシングバリアントの分解剤およびその用途
|
WO2021022163A2
(en)
|
2019-07-31 |
2021-02-04 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
US20220280649A1
(en)
|
2019-08-05 |
2022-09-08 |
Dana-Farber Cancer Institute, Inc. |
Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof
|
WO2021041664A1
(en)
|
2019-08-27 |
2021-03-04 |
The Regents Of The University Of Michigan |
Cereblon e3 ligase inhibitors
|
WO2021041861A1
(en)
|
2019-08-30 |
2021-03-04 |
National University Of Singapore |
N-(2-aminophenyl)-prop-2-enamide derivatives, and uses thereof in the treatment of cancer
|
US20230002371A1
(en)
|
2019-09-13 |
2023-01-05 |
Biotheryx, Inc. |
Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
CN114401960A
(zh)
|
2019-09-16 |
2022-04-26 |
诺华股份有限公司 |
胶降解剂及其使用方法
|
CN110563703B
(zh)
|
2019-09-18 |
2021-04-09 |
浙江省医学科学院 |
基于crbn配体诱导parp-1降解的化合物及制备方法和应用
|
EP4038066A1
(en)
|
2019-10-01 |
2022-08-10 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
JP2022551185A
(ja)
*
|
2019-10-09 |
2022-12-07 |
モンテ ローザ セラピューティクス アーゲー |
イソインドリノン化合物
|
KR20220106976A
(ko)
|
2019-10-28 |
2022-08-01 |
셀진 코포레이션 |
백혈병을 치료하는 방법, 및 요법에 대한 임상 민감도를 예측하기 위한 백혈병 줄기 세포 시그니처의 용도
|
CN110734426B
(zh)
|
2019-10-28 |
2021-02-05 |
浙江省医学科学院 |
乙酰胆碱酯酶降解化合物及其制备方法和应用
|
CN114845716A
(zh)
|
2019-10-28 |
2022-08-02 |
细胞基因公司 |
使用生物标记物预测对2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的临床敏感性
|
CN112812109B
(zh)
|
2019-11-18 |
2022-06-21 |
中国科学院微生物研究所 |
化合物DaP-01及其制备方法和应用
|
US20230357222A1
(en)
|
2020-03-17 |
2023-11-09 |
Dana-Farber Cancer Institute, Inc. |
Selective small molecule degraders of cereblon
|
US20240050428A1
(en)
|
2020-10-07 |
2024-02-15 |
Cullgen (Shanghai), Inc. |
Compounds and methods of treating cancers
|
AU2021372427A1
(en)
|
2020-10-26 |
2023-06-08 |
Dana-Farber Cancer Institute, Inc. |
Compounds for targeted protein degradation of kinases
|